MetaVia Unveils Positive Phase 1 Study Results for DA-1726 at EASL Congress 2026
MetaVia Unveils Positive Phase 1 Study Results for DA-1726 at EASL Congress 2026
MetaVia Inc. (Nasdaq: MTVA), a promising clinical-stage biotechnology firm focused on cardiometabolic disease transformation, showcased its latest findings on DA-1726 at the European Association for the Study of the Liver Congress 2026 (EASL 2026) in Barcelona, Spain, which runs from May 27 to 30. These Phase 1 results suggest a significant advancement in obesity treatment and metabolic dysfunction.
Key Findings
The trial focused on a 48 mg dose of DA-1726, a dual glucagon-like peptide-1 receptor (GLP-1) and glucagon receptor (GCGR) agonist aimed at addressing obesity and metabolic dysfunction-associated steatohepatitis (MASH). Notable outcomes include:
- - Weight Loss: Participants in the 48 mg cohort experienced an average reduction in body weight of up to 9.1% by Day 54, with significant decreases observed as early as Day 26.
- - Waist Circumference: The study also recorded an average waist circumference reduction of 9.8 cm at the study's conclusion.
- - Liver Health: Non-invasive liver assessments indicated early improvements, showcasing DA-1726's potential benefits beyond weight loss.
Safety and Tolerability
MetaVia's Chief Executive Officer, Hyung Heon Kim, emphasized the favorable safety profile of DA-1726, noting that no serious adverse events or discontinuations occurred among participants. Although gastrointestinal side effects were reported, they were mild and transient. Importantly, evaluations showed no significant cardiovascular changes despite glucagon receptor activation, which often raises concerns in treatments targeting metabolic disorders.
Ongoing Research
The promising phase 1 results uphold the ongoing research into DA-1726, highlighting its differentiation as a competitive treatment for obesity. Future titration studies are set to evaluate longer-term dosing strategies, optimizing tolerability while further investigating the durability of its metabolic and liver-related effects. This commitment is critical for MetaVia, as they aim to solidify DA-1726's position as a potential first-in-class therapy in its category.
Chris Fang, MetaVia's Chief Medical Officer, presented the detailed findings, underscoring the significance of these results in reshaping treatment paradigms for obesity and related liver diseases. As the project progresses, there is enthusiasm about the opportunity to bring DA-1726 to a larger patient population.
About DA-1726
DA-1726 is designed for weekly subcutaneous administration, functioning through dual receptor activation to reduce appetite and promote energy expenditure. This approach may yield superior weight loss outcomes compared to existing therapies like semaglutide (Wegovy®) and tirzepatide (Zepbound®). The potential benefits for both weight and liver health make it a noteworthy candidate in the intensive research landscape surrounding metabolic diseases.
Conclusion
The insights gained from the EASL 2026 presentation pave the way for an exciting era in the treatment of obesity and related metabolic disorders. With results suggesting DA-1726’s efficacy and safety, MetaVia Inc. is poised to continue its mission to transform how cardiometabolic conditions are approached, potentially enhancing patient outcomes for millions facing these challenges globally. Future studies will need to confirm these findings and further elucidate the therapeutic impact of this innovative approach.
For more information on the latest developments at MetaVia, visit MetaVia's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.